bosentan anhydrous has been researched along with Ventricular Dysfunction, Left in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Argyropoulou, P; Boutou, AK; Pitsiou, G; Stanopoulos, I | 1 |
| Galiè, N; Guazzi, M | 1 |
| Brauchlin, AE; Nicod, LP; Rochat, T; Soccal, PM; Spiliopoulos, A; Trindade, PT | 1 |
| Caspi, A; Cotter, G; Kaluski, E; Kobrin, I; Krakover, R; Leitman, M; Milo-Cotter, O; Moriconi, T; Rainisio, M; Reizin, L; Vered, Z; Zimlichman, R | 1 |
| Barbe, F; Carayon, A; Choussat, R; Crozatier, B; Hittinger, L; Maistre, G; Su, J | 1 |
| Goldstein, S; Mishima, T; Sabbah, HN; Sharov, VG; Suzuki, G; Tanimura, M; Todor, A | 1 |
| Clair, MJ; de Gasparo, M; Hendrick, JW; King, MK; Mandel, J; McElmurray, JH; Mukherjee, R; New, RB; Sampson, AC; Spinale, FG | 1 |
| Hannan, RD; Krum, H; Lim, S; See, F; Tzanidis, A; Ugoni, AM | 1 |
1 review(s) available for bosentan anhydrous and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Pulmonary hypertension in left heart disease.
Topics: Antihypertensive Agents; Bosentan; Echocardiography, Doppler; Electrocardiography; Endothelin A Receptor Antagonists; Endothelin-1; Endothelium, Vascular; Exercise Test; Heart Valve Prosthesis; Humans; Hypertension, Pulmonary; Mitral Valve; Nitric Oxide; Phosphodiesterase 5 Inhibitors; Pulmonary Wedge Pressure; Radiography, Thoracic; Stroke Volume; Sulfonamides; Vascular Resistance; Vasodilator Agents; Ventricular Dysfunction, Left; Weight Loss | 2012 |
1 trial(s) available for bosentan anhydrous and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.
Topics: Antihypertensive Agents; Bosentan; Double-Blind Method; Female; Heart Failure, Systolic; Humans; Hypertension, Pulmonary; Male; Severity of Illness Index; Sulfonamides; Treatment Outcome; Ultrasonography; Ventricular Dysfunction, Left | 2008 |
6 other study(ies) available for bosentan anhydrous and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Pulmonary hypertension therapy and COPD: still many questions to be answered.
Topics: Bosentan; Exercise; Humans; Hypertension, Pulmonary; Perfusion; Pulmonary Artery; Pulmonary Disease, Chronic Obstructive; Randomized Controlled Trials as Topic; Research Design; Sulfonamides; Treatment Outcome; Ventricular Dysfunction, Left | 2009 |
Severe left ventricular dysfunction secondary to primary pulmonary hypertension: bridging therapy with bosentan before lung transplantation.
Topics: Adult; Antihypertensive Agents; Bosentan; Combined Modality Therapy; Humans; Hypertension, Pulmonary; Lung Transplantation; Male; Severity of Illness Index; Sulfonamides; Ventricular Dysfunction, Left; Ventricular Dysfunction, Right | 2005 |
Acute effects of an endothelin-1 receptor antagonist bosentan at different stages of heart failure in conscious dogs.
Topics: Animals; Bosentan; Cardiac Output; Cardiac Pacing, Artificial; Dogs; Endothelin Receptor Antagonists; Endothelin-1; Endothelins; Female; Heart Failure; Hemodynamics; Male; Protein Precursors; Stroke Volume; Sulfonamides; Vasodilator Agents; Ventricular Dysfunction, Left; Ventricular Pressure | 1998 |
Effects of long-term therapy with bosentan on the progression of left ventricular dysfunction and remodeling in dogs with heart failure.
Topics: Animals; Antihypertensive Agents; Bosentan; Disease Progression; Dogs; Heart Failure; Infusions, Intravenous; Myocardium; Stroke Volume; Sulfonamides; Ventricular Dysfunction, Left; Ventricular Function, Left; Ventricular Remodeling | 2000 |
Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Bosentan; Cardiac Pacing, Artificial; Combined Modality Therapy; Endothelin Receptor Antagonists; Endothelin-1; Heart Failure; Myocardial Contraction; Norepinephrine; Receptor, Endothelin A; Renin; Sulfonamides; Swine; Tetrazoles; Valine; Valsartan; Ventricular Dysfunction, Left | 2000 |
Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1).
Topics: Angiotensin Receptor Antagonists; Animals; Blotting, Northern; Bosentan; Collagen; Endothelin Receptor Antagonists; Female; Fibroblasts; Hemodynamics; Hypertrophy, Left Ventricular; Immunohistochemistry; Macrophages; Monocytes; Myocardial Infarction; Myocardium; Procollagen; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Tetrazoles; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Valine; Valsartan; Ventricular Dysfunction, Left | 2001 |